Sanofi, a multinational pharmaceutical company, is central to numerous deals, advancements, and controversies across the bio-tech sector. Mentioning high-profile collaborations such as licensing a
first-in-class drug from Sino Biopharm for up to $1.53 billion, putting $400M into a Teva-partnered gut disease drug with Blackstone, and selling its Medley unit to Brazil's EMS for over $500M. Sanofi also secured a $1.5B global licensing deal for Sino Biopharm's JAK/ROCK asset and deals involving autoimmune bispecific pact with AI biotech could reach $2.5B. Furthermore, Sanofi secures recommendation for Dupixent's EU approval, however, ceases development of mRNA seasonal flu vaccine, and it also encounters various lawsuits, including Texas accusing them of 'bribing' providers to increase drug prescriptions. Lastly, Sanofi's CEO, Paul Hudson, was ousted, allowing former Merck KGaA chief, Belén Garijo, to take the lead.
Sanofi News Analytics from Fri, 06 Jun 2025 07:00:00 GMT to Fri, 06 Mar 2026 22:57:55 GMT -
Rating 5
- Innovation 8
- Information 7
- Rumor 6
